NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES.

Lund, Sweden – March 20, 2019 – BioInvent International AB (“BioInvent” or the “Company”) (OMXS: BINV) has resolved to approve the Board of Directors’ resolution on a rights issue of up to 131,549,988 shares and to authorize the Board of Directors to resolve on an over-allotment option of up to additionally 43,750,000 shares, to be exercised if the rights issue is over-subscribed.

In accordance with the terms and conditions for the rights issue, each existing share held at the record date, 25 March 2019, entitles to one (1) subscription right, whereby eight (8) subscription rights entitle to subscription for three (3) new shares. The subscription price is SEK 1.60 per share, corresponding to proceeds amounting to MSEK 210 before transaction costs. The subscription period will be from and including 28 March until and including 12 April 2019, with a right for the Board of Directors to extend the subscription period. The rights issue will involve a share capital increase of SEK 10,523,999.04 through the issuance of a maximum number of 131,549,988 new shares.

The general meeting also resolved to authorize the Board of Directors to resolve on an over-allotment option of up to additionally 43,750,000 shares with a subscription price of SEK 1.60 per share, to be exercised if the rights issue is over-subscribed, in order to raise additional proceeds amounting to MSEK 70. The issue can be made without pre-emptive rights for the Company’s shareholders according to the allotment principles that apply to subscription without subscription rights in the rights issue, however, the Board of Directors after full allocation to shareholders (including those who have subscribed for shares by the exercise of subscription rights), shall have the right to meet any new shareholder’s subscription interest if the Board of Directors finds this beneficial to the Company.

Further information will be included in the prospectus that is estimated to be published on or around 21 March 2019.

The minutes from the extraordinary general meeting will be available on the Company’s website, www.bioinvent.com.

The time table below is preliminary.

About BioInvent 

BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer. The Company’s lead program is BI-1206, currently in Phase l/ll for non-Hodgkin lymphoma and chronic lymphatic leukemia. BioInvent’s pre-clinical portfolio is focused on targeting key immune suppressive cells and pathways of the tumor microenvironment, including regulatory T cells, tumor-associated myeloid cells and mechanisms of antibody drug-resistance. The Company has a strategic research collaboration with Pfizer Inc., and partnerships with Transgene, Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates near term revenues from its fully integrated manufacturing unit producing antibodies for third parties for research through to late-stage clinical trials. More information is available at www.bioinvent.com.

For further information, please contact:

BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com

Important information 

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares or other securities in BioInvent International AB. Any invitation to the persons concerned to subscribe for shares in BioInvent will only be made through the prospectus that BioInvent estimates to publish on or around 21 March 2019.

The information in this press release may not be released, published or distributed, directly or indirectly, in or into the United States (including its territories and provinces, every state in the United States and the District of Columbia), Australia, Hong Kong, Japan, Canada, New Zeeland, Singapore or South Africa or any other jurisdiction in which such action is subject to legal restrictions or would require other measures than those required by Swedish law.

This press release does not contain or constitute an offer to acquire or subscribe to securities in the United States. No subscription rights, BTAs (interim shares) or shares have or will be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or the securities legislation of any state or other jurisdiction in the United States may not be offered, subscribed, sold or otherwise transferred, directly or indirectly, in or within the United States, other than pursuant to an exemption from, or in a transaction that is not subject to, the registration requirements under the U.S. Securities Act and in accordance with the securities legislation in the relevant state or any other jurisdiction of the United States. BioInvent does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering in the securities in the United States.

No public offering of securities is made to any country within the European Economic Area (the “EEA”) other than Sweden. In other member states of the EEA which have implemented European Parliament and Council Directive 2003/71/EC (the “Prospectus Directive”), such offering may be made only under the exemption in the Prospectus Directive as well as every relevant implementation measure (including measures to implement European Parliament and Council Directive 2010/73/EU).